This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Digital Media in the Pharmaceutical Industry: Oportunities and Legal Challenges

Abstract

The term digital media is widely understood. According to the open-access encyclopedia Wikipedia digital media shall mean a “form of electronic media where data are stored in digital (as opposed to analog) form and can include the technical aspect of storage and transmission (e.g. hard disk drives or computer networking) of information or to the "end product", such as digital video, augmented reality, digital signage, digital audio, or digital art.” The focus of the following discussion will be on the transmission of information for example by websites and digital communication tools as well as on the use of “end products” like augmented reality applications.

PLS LogoCopyright & permissions

Author

Portrait image of Marc Bauer
Marc Bauer
Legal Director, AMGEN (Europe) GmbH, Switzerland

Dr Marc Bauer is a Director & Senior Legal Counsel with Amgen based in Zug. Before joining Amgen he was 6 years as an external counsel with the international law firm HoganLovells where he advised clients in the pharmaceutical and medical devices industry on all commercial matters including Compliance. The author is part of the International Legal Team covering all markets outside the US. The author leads the support of the commercial functions within Amgen, including marketing, 3rd party relationships and International litigations. He is also part of Amgen's digital media council.

Company

AMGEN (Europe) GmbH

Amgen is the largest independent Biotech company in the world.

Related Papers

Pharmaceutical Marketing and Transparency in Japan
Japan is a promising market for companies, in-spite of the pressures posed by drug prices, competition and patents. The reason may be the large growth of pharmaceuticals, an aging population,...Read more
Portrait image of Marianne Slivkova
Marianne Slivkova
Senior Corporate Counsel, Acorda Therapeutics, USA
Conducting Effective Global Anti–Money Laundering Investigations in a Complex Regulatory Environment
Global anti–money laundering (AML) investigations present complex operational and regulatory challenges driven by cross-border transactions, fragmented data sources, varying legal regimes, data protection and privacy requirements, and cultural barriers to...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Kwanza Burney
Kwanza Burney
Compliance & Risk Professional | M.S.L. Candidate (Fordham Law), Fordham University School of Law, US
“Crisis-Capable Compliance: The CCO at the Crossroads of AI, Ethics, and Leadership”
The role of the Chief Compliance Officer is undergoing a fundamental transformation in the era of artificial intelligence. No longer confined to oversight and enforcement, the CCO is emerging as...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Dolores Guzman
Dolores Guzman
Legal & Compliance Director , Apex America , UK
Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Valentina Lacerca-Allen
Valentina Lacerca-Allen
Title Marketing/ Communication Specialist, Ethiprax LLC., USA